FIXX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Mar 2024 @ 16:00):

Stats
Today's Volume	401 467
Average Volume	29 535.00
Market Cap	3.02M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.230 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.122 (0.74%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Alloway Paul	Buy	23 530	Common Stock
2024-03-25	Alloway Paul	Sell	18 090	Restricted Stock Units
2024-03-25	Michaud Charles Jr	Buy	6 448	Common Stock
2024-03-25	Michaud Charles Jr	Sell	5 360	Restricted Stock Units
2024-01-01	Tzianabos Arthur	Buy	19 140	Common Stock

INSIDER POWER
36.13
Last 94 transactions
Buy: 1 681 707 \| Sell: 632 243

Homology Medicines Inc Correlation

10 Most Positive Correlations
TBNK	0.904
FNWB	0.903
GRPN	0.9
VTRS	0.895
TFSL	0.895
HMST	0.891
APDN	0.889
TCPC	0.886
VERU	0.886
RFIL	0.885

10 Most Negative Correlations
ZGNX	-0.915
ADMS	-0.913
UNCY	-0.886
RESN	-0.877
TYHT	-0.876
ORTX	-0.874
BLCT	-0.87
PLPC	-0.869
CNST	-0.864
CNCE	-0.861

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Homology Medicines Inc Correlation - Currency/Commodity

-0.15
( neutral )

0.08
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.37
( neutral )

-0.21
( neutral )

Homology Medicines Inc Financials

Annual	2023
Revenue:	$1.16M
Gross Profit:	$578 000 (50.00 %)
EPS:	$-1.950

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.280

Q3	2023
Revenue:	$0
Gross Profit:	$-136 000 (0.00 %)
EPS:	$-0.570

Q2	2023
Revenue:	$354 000
Gross Profit:	$-210 000 (-59.32 %)
EPS:	$-0.610

Financial Reports:

No articles found.

Homology Medicines Inc

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.